You are here

Antithrombotic Effects of Optimized Human Apyrase

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44HL076053-02
Agency Tracking Number: HL076053
Amount: $790,435.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2006-2
Timeline
Solicitation Year: 2006
Award Year: 2006
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
APT THERAPEUTICS, INC. 893 NORTH WARSON ROAD
SAINT LOUIS, MO 63141
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 RIDONG CHEN
 (314) 608-6932
 RCHEN@NIDUSCENTER.COM
Business Contact
 RIDONG CHEN
Phone: (314) 812-8054
Email: RCHEN@NIDUSCENTER.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): The goal of the proposed work is to develop a novel antithrombotic drug that is safer and more effective than current therapies. Phase I funding for this project supported the successful development of a novel expression system to facilitate efficient production and purification of an optimized human apyrase as antithrombotic agent. Under Phase II support, we will extend the feasibility studies of Phase I to the development of a commercial Chinese hamster ovary cell line for high yield production. We will then utilize the recombinant protein to determine whether inhibition of platelet activation with the optimized apyrase in vivo attenuates thrombosis after arterial injury in rabbits and pigs. The ultimate goal of this research will be to develop APT102 as a frontline therapy for patients undergoing percutaneous coronary intervention as well as other patients with vascular disorders induced by excessive platelet activation.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government